Current Report Filing (8-k)
20 August 2022 - 7:28AM
Edgar (US Regulatory)
0000012239
false
0000012239
2022-08-09
2022-08-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 9, 2022
AIKIDO PHARMA INC. |
(Exact name of registrant as specified in its charter) |
|
Delaware |
000-05576 |
52-0849320 |
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
One Rockefeller Plaza, 11th Floor, New York, NY |
10020 |
(Address of principal executive offices) |
(Zip Code) |
|
Registrant’s telephone number, including
area code: (703) 993-9325
N/A
(Former name or former address, if changed since
last report.) |
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
Trading
Symbol(s) |
Name of
each exchange on which registered |
Common Stock, $0.0001 par value |
AIKI |
The Nasdaq Capital Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
On August 9, 2022, the board of directors (the “Board”)
of AIkido Pharma Inc. (the “Company”) received an unsolicited proposal from Shalom Auerbach to acquire all of the outstanding
shares of the Company for $8.00 per share in cash.
The Board reviewed and considered Mr. Auerbach’s proposal,
and on August 18, 2022, the Company’s counsel delivered a letter to Mr. Auerbach informing him that the Board determined that it
was not interested in pursuing the offer.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: |
August 19, 2022 |
AIKIDO PHARMA INC. |
|
|
|
|
|
|
By: |
/s/ Anthony Hayes |
|
|
Name: |
Anthony Hayes |
|
|
Title: |
Chief Executive Officer |
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Apr 2023 to Apr 2024